Overview Dividends

(EHAB) Enhabit - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29332G1022

Home Health, Hospice, Therapy, Skilled Nursing, Chronic Care

Health Care Services
Market Cap in USD: 481m

IPO / Inception: 2022-07-01
Return 12m vs S&P 500: 2.73%

EPS (Earnings per Share)

EPS CAGR: -29.26%
EPS Trend: -51.6%

Last SUE: 2.01
Qual. Beats: 1

Revenue

Rev. CAGR: -1.23%
Rev. Trend: -67.5%

Last SUE: -0.84
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	53.8%
Value at Risk 5%th	70.9%
Relative Tail Risk	-19.94%

Reward TTM
Sharpe Ratio	0.58
Alpha	9.76
CAGR/Max DD	-0.18

Character TTM
Hurst Exponent	0.544
Beta	0.654
Beta Downside	0.745

Drawdowns 3y
Max DD	59.30%
Mean DD	38.04%
Median DD	42.04%

Description: EHAB Enhabit December 27, 2025

Enhabit, Inc. (NYSE: EHAB) operates a nationwide network of home health and hospice providers, delivering services such as skilled nursing, wound care, infusion therapy, and rehabilitation, as well as comprehensive end-of-life support that includes pain management, counseling, and spiritual care. The company rebranded from Encompass Health Home Health Holdings in March 2022 and is headquartered in Dallas, Texas.

As of Q3 2024, Enhabit reported total revenue of $1.12 billion, up 7 % year-over-year, driven primarily by higher case-mix intensity and a 4 % increase in patient days. Adjusted EBITDA margin stood at 6.8 %, reflecting ongoing cost-control initiatives amid a tight labor market. The firm’s average daily census (ADC) grew to 14.5 patients per agency, a metric that tracks utilization efficiency in the home-health sector.

Key industry drivers include the U.S. aging demographic-people aged 65+ are projected to reach 21 % of the population by 2030-alongside rising Medicare Advantage enrollment, which often favors home-based care to reduce hospital costs. Conversely, the sector faces headwinds from a persistent skilled-nurse shortage and potential policy shifts in Medicare reimbursement rates.

For a deeper dive into EHAB’s valuation metrics, see the ValueRay platform.

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (-11.9m TTM) > 0 and > 6% of Revenue (6% = 62.9m TTM)

FCFTA 0.05 (>2.0%) and ΔFCFTA 0.68pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 7.46% (prev 6.30%; Δ 1.17pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.05 (>3.0%) and CFO 62.2m > Net Income -11.9m (YES >=105%, WARN >=100%)

Net Debt (459.6m) to EBITDA (59.2m) ratio: 7.76 <= 3.0 (WARN <= 3.5)

Current Ratio 1.58 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (51.1m) change vs 12m ago 1.79% (target <= -2.0% for YES)

Gross Margin 48.43% (prev 46.56%; Δ 1.88pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 82.75% (prev 79.52%; Δ 3.22pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 0.93 (EBITDA TTM 59.2m / Interest Expense TTM 36.5m) >= 6 (WARN >= 3)

Altman Z'' 1.17

(A) 0.06 = (Total Current Assets 213.7m - Total Current Liabilities 135.5m) / Total Assets 1.23b

(B) 0.11 = Retained Earnings (Balance) 132.4m / Total Assets 1.23b

(D) 0.21 = Book Value of Equity 132.9m / Total Liabilities 631.0m

Total Rating: 1.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 42.86

1. Piotroski 4.50pt

2. FCF Yield 6.15%

3. FCF Margin 5.52%

4. Debt/Equity 0.91

5. Debt/Ebitda 7.76

6. ROIC - WACC (= -2.15)%

7. RoE -2.18%

8. Rev. Trend -67.53%

9. EPS Trend -51.60%

What is the price of EHAB shares?

As of December 29, 2025, the stock is trading at USD 9.38 with a total of 214,902 shares traded.
Over the past week, the price has changed by -0.11%, over one month by +4.92%, over three months by +16.52% and over the past year by +21.98%.

Is EHAB a buy, sell or hold?

Enhabit has received a consensus analysts rating of 3.40. Therefor, it is recommend to hold EHAB.

Strong Buy: 1
Buy: 0
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the EHAB price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	9.8	3.9%
Analysts Target Price	9.8	3.9%
ValueRay Target Price	9.7	3.4%

EHAB Fundamental Data Overview December 27, 2025

Market Cap USD = 480.5m (480.5m USD * 1.0 USD.USD)
P/E Forward = 18.1818
P/S = 0.4586
P/B = 0.8464
Beta = 1.292
Revenue TTM = 1.05b USD
EBIT TTM = 33.8m USD
EBITDA TTM = 59.2m USD
Long Term Debt = 441.5m USD (from longTermDebt, last quarter)
Short Term Debt = 35.2m USD (from shortTermDebt, last quarter)
Debt = 516.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 459.6m USD (from netDebt column, last quarter)
Enterprise Value = 940.1m USD (480.5m + Debt 516.5m - CCE 56.9m)
Interest Coverage Ratio = 0.93 (Ebit TTM 33.8m / Interest Expense TTM 36.5m)
FCF Yield = 6.15% (FCF TTM 57.8m / Enterprise Value 940.1m)
FCF Margin = 5.52% (FCF TTM 57.8m / Revenue TTM 1.05b)
Net Margin = -1.14% (Net Income TTM -11.9m / Revenue TTM 1.05b)
Gross Margin = 48.43% ((Revenue TTM 1.05b - Cost of Revenue TTM 540.3m) / Revenue TTM)
Gross Margin QoQ = 48.48% (prev 46.94%)
Tobins Q-Ratio = 0.77 (Enterprise Value 940.1m / Total Assets 1.23b)
Interest Expense / Debt = 1.61% (Interest Expense 8.30m / Debt 516.5m)
Taxrate = 21.62% (3.20m / 14.8m)
NOPAT = 26.5m (EBIT 33.8m * (1 - 21.62%))
Current Ratio = 1.58 (Total Current Assets 213.7m / Total Current Liabilities 135.5m)
Debt / Equity = 0.91 (Debt 516.5m / totalStockholderEquity, last quarter 566.8m)
Debt / EBITDA = 7.76 (Net Debt 459.6m / EBITDA 59.2m)
Debt / FCF = 7.95 (Net Debt 459.6m / FCF TTM 57.8m)
Total Stockholder Equity = 546.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.97% (Net Income -11.9m / Total Assets 1.23b)
RoE = -2.18% (Net Income TTM -11.9m / Total Stockholder Equity 546.5m)
RoCE = 3.42% (EBIT 33.8m / Capital Employed (Equity 546.5m + L.T.Debt 441.5m))
RoIC = 2.56% (NOPAT 26.5m / Invested Capital 1.03b)
WACC = 4.71% (E(480.5m)/V(997.0m) * Re(8.42%) + D(516.5m)/V(997.0m) * Rd(1.61%) * (1-Tc(0.22)))
Discount Rate = 8.42% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.09%
[DCF Debug] Terminal Value 76.32% ; FCFE base≈55.7m ; Y1≈53.5m ; Y5≈52.5m
Fair Price DCF = 17.24 (DCF Value 872.6m / Shares Outstanding 50.6m; 5y FCF grow -5.17% → 3.0% )
EPS Correlation: -51.60 | EPS CAGR: -29.26% | SUE: 2.01 | # QB: 1
Revenue Correlation: -67.53 | Revenue CAGR: -1.23% | SUE: -0.84 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.13 | Chg30d=+0.009 | Revisions Net=+2 | Analysts=3
EPS next Year (2026-12-31): EPS=0.58 | Chg30d=+0.020 | Revisions Net=+2 | Growth EPS=+3.9% | Growth Revenue=+4.0%

Additional Sources for EHAB Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle